LONDON, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Brighter (BRIG:SS) is a healthtech company developing solutions for chronic diseases. Its initial strategy is the launch of Actiste, a mobile-connected glucose meter and insulin injection device for diabetes, which the company has submitted for CE certification. Its CE-marked cloud-based platform called the Benefit Loop and associated companion applications collect, manage and analyse data for the purpose of sharing critical treatment information with friends, relatives, caregivers and healthcare providers in an effort to improve self-management outcomes.

We arrive at an initial valuation of SEK1046.7m or SEK15.08 per share based on a risk-adjusted NPV analysis of Brighter’s multi-tier product offerings and target markets. We expect the company to require SEK180m in additional capital before profitability in 2021.

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website
www.edisoninvestmentresearch.com

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Maxim Jacobs, +1 646 653 7027
Nathaniel Calloway, +1 646 653 7036
Briana Warschun, +1 646 653 7031
healthcare@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on: 
LinkedIn  https://www.linkedin.com/company/edison-investment-research
Twitter    www.twitter.com/Edison_Inv_Res
YouTube  www.youtube.com/edisonitv